Fda Approval In Hcl, Nda In Urothelial Carcinoma, And 2018 Ilca Conference Highlights

FDA Approval in HCL, NDA in Urothelial Carcinoma, and 2018 ILCA Conference Highlights

FDA Approvals in Bladder Cancer and NSCLC, and 2019 ELCC Highlights

FDA Approvals in Urothelial Cancer and GIST, Promising Data in Urothelial Carcinoma, and More

The FDA Approval of Atezolizumab in Bladder Cancer

FDA Approval of Durvalumab for Advanced Bladder Cancer

FDA Approval of Durvalumab for Bladder Cancer

FDA Approvals in Urothelial Cancer and Prostate Cancer, Priority Review in CRC, and More

Liquid biopsies and tumor-informed ctDNA profiling in metastatic urothelial carcinoma

FDA Approval in Prostate Cancer, NDA Submitted in CLL and Follicular Lymphoma, and More

FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More

FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

2018 Cholangiocarcinoma Foundation Annual Conference #6 - Day 1 - FDA Drug Approval Process

Cholangiocarcinoma Foundation

FDA Approvals in Bladder Cancer and Hodgkin Lymphoma, Breakthrough Designation in AML, and More

FDA Approvals in Breast Cancer and NSCLC, NDA Accepted in HCC, and More

Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

FDA Approvals in Ovarian Cancer, Merkel Cell Carcinoma, ITP, and More

FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More

FDA Approvals in Prostate Cancer and Endometrial Cancer, and Priority Review in Urothelial Cancer

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

U.S. Food and Drug Administration